Engineering Confidence for
Cell Therapy Programs
DES Pharma supports autologous and allogeneic cell therapy programs across process development,
analytics, supply chain, quality assurance, and medical safety, from preclinical IND through BLA
readiness and commercial launch.
CAR-T
Auto
Allo
IND–BLA
Cell Therapy Expertise CMC Consulting Built Around Living Cell Products
CAR-T, TCR-T, TIL, NK, and Treg programs each carry distinct manufacturing demands, CQA profiles, and regulatory expectations. DES Pharma brings consulting depth across all major modalities and both manufacturing models, without conflating them.
Autologous programs demand patient-specific scheduling, chain of identity, and vein-to-vein time management. Allogeneic programs require master cell banking, scalable closed-system expansion, and off-the-shelf distribution readiness. Cell therapy CQAs (viability, CAR expression, VCN, potency) are defined by manufacturing decisions made in development, not corrected downstream.
Our ServicesEnd-to-End Cell Therapy
CMC Support
Six coordinated service areas covering the full development and
commercialization lifecycle of cell therapy programs.
Program & Process Development
From leukapheresis qualification and transduction platform selection through cryopreservation, tech transfer, process characterization, and PPQ readiness.
- Starting material qualification & leukapheresis handling
- Lentiviral / retroviral / mRNA / CRISPR platforms
- G-Rex, Cocoon, CliniMACS Prodigy support
- Cryopreservation development & formulation
Analytics & Quality Control
ATP/TPP-aligned analytical programs: flow cytometry, CAR expression, potency assays, VCN by ddPCR, RCL/RCR, and rapid lot release for time-constrained autologous programs.
- Immunophenotyping, CAR expression & CD4/CD8 ratio
- Potency: cytotoxicity, cytokine release, xCELLigence
- VCN by ddPCR; RCL/RCR detection (TZM-bl)
- Rapid / provisional lot release strategy
Supply Chain & Procurement
Apheresis qualification, chain of identity systems, GMP lentiviral vector supply, ISTA-7E qualified cryogenic logistics, CDMO selection, and slot-based scheduling.
- Apheresis qualification & COI / COC systems
- GMP vector CDMO supply & quality agreements
- LN2 dry shippers & cold-chain validation
- Slot-based scheduling & patient logistics
Quality Assurance
GMP and cGTP compliance, patient-specific batch records, COI/COC QA, rapid lot release, deviation and CAPA management, supplier qualification, and CBER/OTAT inspection readiness.
- GMP / cGTP systems & COI batch records
- Rapid lot release & provisional release procedures
- Deviation, OOS & CAPA management
- CPV, APR, PQR for commercial programs
Medical Safety & Pharmacovigilance
CRS and ICANS safety oversight, REMS program design, DSMB support, long-term follow-up protocols, SUSAR reporting, and inspection-ready PV systems for cell therapy programs.
- CRS / ICANS protocol design & site training
- REMS strategy, design & FDA submission
- LTFU program design (15-year follow-up)
- QPPV, PSMF & global PV operations
Phase-Appropriate Across the Lifecycle
We calibrate scope, depth, and deliverables to where you are in development, from first IND preparation through BLA submission and post-approval lifecycle management.
- Preclinical / IND: process & analytics foundation
- Phase 1/2: CDMO tech transfer, COI, lot release
- Phase 3 / PPQ: characterization, control strategy
- BLA / Commercial: Module 3, CPV, OTAT inspections
Why DES Pharma Built for the Demands of Living Cell Products
Cell therapy programs fail at the intersection of biology, operations, and regulation, not because the science is wrong, but because the systems around it were not built for a living product. DES Pharma closes that gap with modality-specific depth across every function.
Autologous Operational Depth
Chain of identity as a patient safety obligation. Slot-based manufacturing scheduling. Rapid lot release designed around the infusion date. We build autologous systems that hold up under CBER/OTAT review.
Allogeneic Scale-Up
Master cell banking, closed-system scalable expansion, and off-the-shelf distribution readiness. Allogeneic QA frameworks are built separately from autologous programs because the two are operationally distinct.
Cryogenic & Supply Chain
ISTA-7E qualified LN2 dry shippers, cold-chain validation, and GMP lentiviral vector supply strategy. A cold chain excursion in autologous cell therapy is irreversible. Prevention is the only strategy.
CBER / OTAT Submissions
IND sections, RMAT designation support, Type B meetings, BLA CMC packages, and pre-approval inspection preparation: documentation calibrated to OTAT reviewer expectations, not transplanted from protein analytics programs.
How We WorkHow DES Pharma Engages on Cell Therapy Programs
We begin by understanding your program’s specific context (molecule, stage, manufacturing model, and regulatory history) before recommending a CMC strategy.
Program Assessment & Gap Analysis
Review your existing CMC data, IND documentation, and manufacturing history to identify gaps against phase-appropriate expectations and your CBER/OTAT regulatory pathway.
CMC Strategy & Roadmap
Define a fit-for-purpose plan covering process development, analytics, supply chain, QA, and regulatory filing timeline, integrated with your clinical plan and manufacturing model.
Technical Execution & Oversight
Lead, support, or oversee workstreams: from directing CDMO activities and reviewing batch data to authoring IND sections and BLA CMC modules in real time.
Regulatory References
21 CFR 1271
21 CFR 600
Biological product standards: lot release, potency, and identity for BLA-regulated cell therapies
ICH Q5A · Q5E
RMAT
Regenerative Medicine Advanced Therapy: expedited CBER review with enhanced Type B meeting access
CBER Potency
Get Started Ready to Advance Your Cell Therapy Program?
Whether you are preparing your first IND or finalizing a BLA submission, our consultants are ready to assess your program and identify the highest-value areas for support.